$AMRZ

Jenisch Jan Philipp purchased $1.1M of AMRZ

Jenisch Jan Philipp (Chairman & CEO) purchased 26,000 shares of Amrize Ltd (AMRZ) at an average of $42.46 ($42.37–$42.53, $1.10M total) across 3 trades on 2026-09-02.

Original reporting
SEC EDGAR · Jenisch Jan Philipp
Published Sep 3, 2026, 4:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 5:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMRZ
Bullish
high confidence
Mentioned
$AMRZ
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZBullishMed
01

Why it matters

The purchase adds to the CEO's ownership, suggesting confidence and possibly influencing investor sentiment.

02

Market read

Insider purchase of $1.1M in a micro‑cap can move the stock, offering a short‑term trading edge.

03

What to watch

Potential upcoming dilution or financing events could offset the positive signal.

Relevance 7/10Novelty 8/10Timing: post-filing 2026-09-03

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$AMRZBullishHigh confidence
Context

Chairman & CEO Jan Philipp Jenisch bought 26,000 shares for $1.1M, increasing his stake to 1,767,000 shares.

Expected impact

Potential modest price lift as market absorbs insider buying.

Evidence & confidence

The transaction size relative to the micro‑cap float is material and the insider is the top executive, indicating strong conviction.

Market effects

None

None

None

Counterpoint

Insider buying may be routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Amrize Ltd

    Issuer of the Form 4 filing.

  • Jan Philipp Jenisch

    Chairman & CEO of Amrize Ltd, insider purchaser.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.